ClinicalTrials.gg
CompletedNCT07513571Updated Aug 4, 2026

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

A Phase 1 interventional study of AZD4954 and Laroprovstat in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.

Enrollment
8th of 11
31 · median 59
Started
2026
with 1 other
Phase 1
8 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
11 of 11
AstraZeneca

Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 8th largest by enrollment, is one of 2 that started in 2026, is one of 8 in phase 1, and was the 11th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About laroprovstat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing laroprovstat in Dyslipidemias as a file.
02

Study summary

The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.

Read the detailed description

This is an open-label, fixed-sequence, 2 period and 2 cohort study in healthy participants.

Each participant in each cohort will receive treatments in a fixed order during the 2 treatment periods as follows:

  • Cohort 1: Treatment A followed by Treatment C.
  • Cohort 2: Treatment B followed by Treatment C.

The following treatments will be given during the study:

  • Treatment A: single dose of AZD4954 alone.
  • Treatment B: single dose of laroprovstat alone.
  • Treatment C: single doses of laroprovstat + AZD4954.

The study will comprise of a Screening Period, two Treatment Periods and follow-up visits.

03

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Drug-drug interaction
  • Dyslipidemias
  • Hypercholesterolemia
  • Lipoprotein (a)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All females must have a negative pregnancy test at the Screening Visit.
  • Females of must not be lactating and if heterosexually active must agree to use an approved method of highly effective .
  • Females of non-childbearing potential must be confirmed as or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.
  • Have a between 18 and 35 kg/m2 inclusive and weigh at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Participants with known bleeding or coagulation disorders.
  • Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.
  • Any positive result on Screening for serum surface antigen (HBsAg), hepatitis B core antibody (HBcAb), virus (HCV), or (HIV).
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead at screening.
  • Participants who are current smokers or have used any tobacco or nicotine-containing products (including e-cigarettes) within 3 months prior to screening; known or suspected history of alcohol or drug abuse; positive screen for drugs of abuse, alcohol, or cotinine at screening or on each admission to the Clinical Unit.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs of a similar chemical structure or class to AZD4954 or laroprovstat.
  • Participants who have previously received AZD4954.
  • Treatment with any lipid-lowering therapy or laroprovstat within the 3 months prior to the Screening Visit.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Cohort 1: Treatment Sequence AC

    Participant will receive single dose of AZD4954 alone (Treatment A) followed by single doses of laroprovstat+AZD4954 (Treatment C).

    Drug: AZD4954 · Drug: Laroprovstat

  • Experimental
    Cohort 2: Treatment Sequence BC

    Participant will receive single dose of laroprovstat alone (Treatment B) followed by single doses of laroprovstat+AZD4954 (Treatment C).

    Drug: AZD4954 · Drug: Laroprovstat

Interventions

  • AZD4954 will be administered orally.

  • Laroprovstat will be administered orally.

    Also known as: AZD0780

06

What researchers measure

Primary outcomes

  1. Area under concentration time curve from time 0 to infinity (AUCinf) of AZD4954

    To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.

    Time frame: Cohort 1: Day 1 to Day 41

  2. Maximum observed drug concentration (Cmax) of AZD4954

    To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.

    Time frame: Cohort 1: Day 1 to Day 41

  3. AUCinf of laroprovstat

    To assess the effect of a single dose of oral AZD4954 on the PK of a single dose of oral laroprovstat in healthy participants.

    Time frame: Cohort 2: Day 1 to Day 25

  4. Cmax of laroprovstat

    To assess the effect of a single dose of oral AZD4954 on the PK of a single dose of oral laroprovstat in healthy participants.

    Time frame: Cohort 2: Day 1 to Day 25

Secondary outcomes

  1. Area under concentration curve from time 0 to the last quantifiable concentration (AUClast) of AZD4954

    To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.

    Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31

  2. Apparent total body clearance (CL/F) of AZD4954

    To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.

    Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31

  3. Terminal elimination half-life (t½λz) of AZD4954

    To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.

    Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31

  4. Time to reach maximum observed concentration (tmax) of AZD4954

    To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.

    Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31

  5. Time of last quantifiable concentration (tlast) of AZD4954

    To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.

    Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31

  6. Time delay between drug administration and the first observed concentration (tlag) of AZD4954

    To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.

    Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31

  7. Apparent volume of distribution based on the terminal phase (Vz/F) of AZD4954

    To describe the PK of AZD4954 when administered alone and in combination with laroprovstat.

    Time frame: Cohort 1: Day 1 to Day 41; Cohort 2: Day 11 to Day 31

  8. AUClast of laroprovstat

    To describe the PK of laroprovstat when administered alone and in combination with AZD4954.

    Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25

  9. CL/F of laroprovstat

    To describe the PK of laroprovstat when administered alone and in combination with AZD4954.

    Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25

  10. t½λz of laroprovstat

    To describe the PK of laroprovstat when administered alone and in combination with AZD4954.

    Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25

  11. tmax of laroprovstat

    To describe the PK of laroprovstat when administered alone and in combination with AZD4954.

    Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25

  12. tlast of laroprovstat

    To describe the PK of laroprovstat when administered alone and in combination with AZD4954.

    Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25

  13. tlag of laroprovstat

    To describe the PK of laroprovstat when administered alone and in combination with AZD4954.

    Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25

  14. Vz/F of laroprovstat

    To describe the PK of laroprovstat when administered alone and in combination with AZD4954.

    Time frame: Cohort 1: Day 21 to Day 35; Cohort 2: Day 1 to Day 25

  15. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    To assess the safety and tolerability of AZD4954 alone and in combination with laroprovstat; and safety and tolerability of laroprovstat alone and in combination with AZD4954 following oral administration of single doses in healthy participants.

    Time frame: Cohort 1: Up to Day 83; Cohort 2: Up to Day 73

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Jul 2026, 2 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartActual
Apr 10, 2026
Primary completionActual
Jul 8, 2026
CompletionActual
Jul 8, 2026
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07513571
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Apr 10, 2026
Primary completion
Jul 8, 2026
Completion
Jul 8, 2026
Last update
Aug 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD4954 · Laroprovstat

Start the discussion